According to research report the global IVD quality control market is expected to reach USD 1.04 billion by 2022, at a CAGR of 3.5% from 2017 to 2022. The global IVD quality controls market is oligopolistic in nature with very few players accounting for a major share of the market. Bio-Rad Laboratories, Inc. (U.S.), Randox Laboratories (U.K.), and Thermo Fisher Scientific, Inc. (U.S.) are the major players in this market. A majority of the leading players in this market are based in developed countries across North America and Europe.
In 2016, Bio-Rad Laboratories held the leading position in the IVD quality controls market. This can be attributed to its highly diversified quality controls portfolio, which includes controls for immunoassay, therapeutic drug monitoring, serum chemistry, and urine chemistry; urinalysis controls; cardiac assessment quality controls; immunology/protein controls; hematology, blood gas, diabetes/hemoglobin, and infectious disease controls; molecular quality controls; and specialty quality controls. Moreover, the company has a wide geographic presence across North America, Europe, Asia-Pacific, and Latin America, which enables it to cater to customers across the globe. The company also offers third party quality controls, data management solutions, educational services, and customer support to clinical laboratories.
In 2016, Randox Laboratories held the second largest share of the IVD quality controls market. The company is a leading quality control manufacturer that offers products through three groups, namely, Acusera Internal Quality Control Sera, Acusera 24·7 Inter laboratory Data Management & Peer Group Reporting Package, and RIQAS External Quality Assessment/Proficiency Testing Scheme. It offers customized quality controls for laboratories across the globe. The company continuously focuses on R&D activities to enhance its existing products and also rapidly bring new products to the market.
Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198032582
In the past three years, a majority of the top players adopted new product launches, agreements, partnerships, geographic expansions, and acquisitions as their key growth strategies. New product launches was the majorly adopted strategy by key players in the IVD quality controls market. For instance, in February 2017, Technopath Clinical Diagnostics (Ireland) launched the IAMQC software used to provide laboratory managers and technologists with a range of QC software tools to analyze their QC results in real-time. Similarly, in November 2016, Randox Laboratories launched its Liquid HbA1c Control which is used to monitor patients with diabetes.